Background Novel oral anticoagulants are the cornerstone of therapy for non‐valvular atrial
fibrillation patients to lower the risk of ischaemic stroke. Given the lack of head‐to‐head …

Objectives The aim of this study was to assess apixaban prescribing practices for stroke
prevention in patients with non-valvular atrial fibrillation (NVAF), and to examine the factors …

BACKGROUND: Recommendations for apixaban dosing on the basis of kidney function are
inconsistent between the US Food and Drug Administration and European Medicines …

Abstract Introduction Reduced-dose (Low-dose [LD]) apixaban is recommended in patients
with atrial fibrillation (AF) who fulfill 2 of 3 criteria: age≥ 80 years, body weight≤ 60 kg, and …

In addition to warfarin, there are four non-vitamin K antagonist oral anticoagulants (NOACs)
available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited …

Background: Various treatment strategies to treat AF and reduce its complications have
been developed, including anticoagulant administration. Non-Vitamin K antagonist oral …

Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in
Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) …

Background and Purpose: The effects of direct oral anticoagulants in nonvalvular atrial
fibrillation should be assessed in actual conditions of use. France has near-universal …

Aims History of bleeding strongly influences decisions for anticoagulation in atrial fibrillation
(AF). We analyzed outcomes in relation to history of bleeding and randomization in …

Background: Compared with the general population, patients with advanced chronic kidney
disease have a> 10-fold higher burden of atrial fibrillation. Limited data are available …